Home LiteratureArticle Details
PMID: 19829371 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease.

Nature ·Vol. 461 ·No. 7266 ·2009-10-15 ·Pages 916-22

Perrin RJ, Fagan AM, Holtzman DM

Abstract

Alzheimer's disease affects millions of people around the world. Currently, there are no treatments that prevent or slow the disease. Like other neurodegenerative diseases, Alzheimer's disease is characterized by protein misfolding in the brain. This process and the associated brain damage begin years before the substantial neurodegeneration that accompanies dementia. Studies using new neuroimaging techniques and fluid biomarkers suggest that Alzheimer's disease pathology can be detected preclinically. These advances should allow the design of new clinical trials and early mechanism-based therapeutic intervention.

MeSH Terms
Alzheimer Disease/diagnosis,drug therapy,metabolism,physiopathology Amyloid beta-Peptides/cerebrospinal fluid,metabolism Humans Inflammation/metabolism,pathology Oxidative Stress Prognosis Proteomics tau Proteins/cerebrospinal fluid,metabolism
Chemicals
Amyloid beta-Peptides tau Proteins
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Perrin Richard J
Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St Louis, Missouri 63110, USA.
Fagan Anne M
Holtzman David M
References (73)
73 references, click to expand
  1. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Arch Neurol. 2007 Mar;64(3):354-62 PMID: 17353377
  2. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease.
    J Mol Neurosci. 2001 Oct;17(2):101-18 PMID: 11816784
  3. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease.
    Ann Neurol. 2007 Feb;61(2):120-9 PMID: 17167789
  4. Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment.
    Neurodegener Dis. 2007;4(6):406-12 PMID: 17934323
  5. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.
    JAMA. 1989 Nov 10;262(18):2551-6 PMID: 2810583
  6. Amyloid-beta dynamics correlate with neurological status in the injured human brain.
    Science. 2008 Aug 29;321(5893):1221-4 PMID: 18755980
  7. The Clinical Dementia Rating (CDR): current version and scoring rules.
    Neurology. 1993 Nov;43(11):2412-4 PMID: 8232972
  8. Diagnosis of Alzheimer's disease.
    Arch Neurol. 1985 Nov;42(11):1097-105 PMID: 2864910
  9. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease.
    Proteomics Clin Appl. 2007 Nov;1(11):1373-84 PMID: 21136637
  10. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study.
    Neurobiol Dis. 2008 Dec;32(3):412-9 PMID: 18786637
  11. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT.
    Neuroimage. 2005 Dec;28(4):1014-21 PMID: 16129627
  12. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Lancet Neurol. 2006 Mar;5(3):228-34 PMID: 16488378
  13. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.
    Ann Neurol. 2003 Jan;53(1):81-90 PMID: 12509851
  14. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease.
    J Neuropathol Exp Neurol. 1997 Oct;56(10):1095-7 PMID: 9329452
  15. Proteome-based plasma biomarkers for Alzheimer's disease.
    Brain. 2006 Nov;129(Pt 11):3042-50 PMID: 17071923
  16. Complement activation in very early Alzheimer disease.
    Alzheimer Dis Assoc Disord. 2005 Apr-Jun;19(2):55-66 PMID: 15942322
  17. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.
    Nat Med. 2007 Nov;13(11):1359-62 PMID: 17934472
  18. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity.
    Ann Neurol. 2000 Nov;48(5):809-12 PMID: 11079549
  19. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.
    Nat Med. 2006 Jul;12(7):856-61 PMID: 16799555
  20. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.
    Neurobiol Aging. 2009 Jul;30(7):1026-36 PMID: 19376612
  21. Cerebrospinal fluid C3a increases with age, but does not increase further in Alzheimer's disease.
    Neurobiol Aging. 1997 Sep-Oct;18(5):555-7 PMID: 9390784
  22. Targeted proteomics in Alzheimer's disease: focus on amyloid-beta.
    Expert Rev Proteomics. 2008 Apr;5(2):225-37 PMID: 18466053
  23. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.
    Neurology. 1991 Apr;41(4):479-86 PMID: 2011243
  24. Trajectories of brain loss in aging and the development of cognitive impairment.
    Neurology. 2008 Mar 11;70(11):828-33 PMID: 18046010
  25. Expression of monoamine oxidase B activity in astrocytes of senile plaques.
    Acta Neuropathol. 1990;80(4):419-25 PMID: 2239154
  26. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.
    Ann Neurol. 2009 Jul;66(1):48-54 PMID: 19360898
  27. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.
    Neurology. 2007 Aug 14;69(7):631-9 PMID: 17698783
  28. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory.
    J Neurosci. 2005 Aug 24;25(34):7709-17 PMID: 16120771
  29. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10966-71 PMID: 11526211
  30. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
    Ann Neurol. 2006 Mar;59(3):512-9 PMID: 16372280
  31. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease.
    Nature. 2008 Feb 7;451(7179):720-4 PMID: 18256671
  32. Mild cognitive impairment: clinical characterization and outcome.
    Arch Neurol. 1999 Mar;56(3):303-8 PMID: 10190820
  33. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.
    Neurology. 2007 Mar 13;68(11):828-36 PMID: 17353470
  34. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
    Science. 2002 Jul 19;297(5580):353-6 PMID: 12130773
  35. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease.
    Ann Neurol. 1999 Sep;46(3):412-6 PMID: 10482274
  36. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease.
    Cell. 1988 Feb 26;52(4):487-501 PMID: 3257719
  37. Searching for a baseline: functional imaging and the resting human brain.
    Nat Rev Neurosci. 2001 Oct;2(10):685-94 PMID: 11584306
  38. The subunits of alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein, native and transformed alpha2-macroglobulin and interleukin 6 in Alzheimer's disease.
    Brain Res. 1997 Nov 28;777(1-2):223-7 PMID: 9449432
  39. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.
    Amyloid. 2000 Dec;7(4):245-58 PMID: 11132093
  40. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?
    Neurology. 2003 Apr 22;60(8):1374-7 PMID: 12707450
  41. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301.
    Clin Pharmacol Ther. 2009 May;85(5):506-12 PMID: 19129751
  42. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Arch Neurol. 2009 Mar;66(3):382-9 PMID: 19273758
  43. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients.
    Neuroreport. 2002 Apr 16;13(5):611-5 PMID: 11973456
  44. Frequency of stages of Alzheimer-related lesions in different age categories.
    Neurobiol Aging. 1997 Jul-Aug;18(4):351-7 PMID: 9330961
  45. APP processing and synaptic function.
    Neuron. 2003 Mar 27;37(6):925-37 PMID: 12670422
  46. Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies.
    Neuropsychologia. 2008;46(6):1624-35 PMID: 18206188
  47. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease.
    Neuron. 2006 Feb 16;49(4):489-502 PMID: 16476660
  48. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.
    Neurology. 2006 Aug 8;67(3):446-52 PMID: 16894106
  49. PET of brain amyloid and tau in mild cognitive impairment.
    N Engl J Med. 2006 Dec 21;355(25):2652-63 PMID: 17182990
  50. Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients.
    J Neurol Sci. 2008 Jan 15;264(1-2):9-17 PMID: 17727889
  51. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.
    Ann Neurol. 2009 Feb;65(2):176-83 PMID: 19260027
  52. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients.
    Am J Pathol. 1999 Sep;155(3):863-8 PMID: 10487843
  53. No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls.
    Ann Neurol. 2000 Dec;48(6):950 PMID: 11117557
  54. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease.
    J Neurosci. 1996 Jul 15;16(14):4491-500 PMID: 8699259
  55. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.
    J Neurochem. 1993 Nov;61(5):1828-34 PMID: 8228996
  56. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease.
    J Neurol. 2008 Nov;255(11):1712-20 PMID: 19156487
  57. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta.
    Neurogenetics. 2009 Feb;10(1):13-7 PMID: 18813964
  58. Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain.
    J Med Chem. 2004 Apr 22;47(9):2228-35 PMID: 15084121
  59. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease.
    Ann Neurol. 2008 May;63(5):621-31 PMID: 18300284
  60. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease.
    J Alzheimers Dis. 2005 Apr;7(2):125-33; discussion 173-80 PMID: 15851850
  61. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study.
    Neurology. 2007 May 29;68(22):1902-8 PMID: 17536046
  62. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease.
    Lancet. 1999 Jun 19;353(9170):2125 PMID: 10382699
  63. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease.
    Neurosci Lett. 2001 May 18;304(1-2):102-6 PMID: 11335065
  64. The brain's default network: anatomy, function, and relevance to disease.
    Ann N Y Acad Sci. 2008 Mar;1124:1-38 PMID: 18400922
  65. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo.
    Neuron. 2005 Dec 22;48(6):913-22 PMID: 16364896
  66. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease.
    J Neurosci Res. 2002 Nov 1;70(3):447-50 PMID: 12391605
  67. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease.
    Neurology. 1988 Nov;38(11):1682-7 PMID: 3185902
  68. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Arch Neurol. 2007 Mar;64(3):343-9 PMID: 17210801
  69. Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state.
    Neurobiol Aging. 1994 Sep-Oct;15(5):609-14 PMID: 7824052
  70. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.
    Ann Neurol. 1995 Oct;38(4):643-8 PMID: 7574461
  71. Longitudinal CSF isoprostane and MRI atrophy in the progression to AD.
    J Neurol. 2007 Dec;254(12):1666-75 PMID: 17994313
  72. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo.
    FASEB J. 1998 Dec;12(15):1777-83 PMID: 9837868
  73. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
    Ann Neurol. 2004 Mar;55(3):306-19 PMID: 14991808
Article Info
Journal
Nature
Abbr.
Nature
ISSN
1476-4687
DOI
10.1038/nature08538
Published
2009-10-15
Pages
916-22
Language
English
Region
England
NLM ID
0410462
PMCID
PMC2810658
Subset
IM
Grants
NIA NIH HHS · P01-AG03991 · United States
NIA NIH HHS · P01 AG026276-05 · United States
NIA NIH HHS · P50AG00568125 · United States
NIA NIH HHS · P01-AG026276 · United States
NIA NIH HHS · P01 AG026276 · United States
NINDS NIH HHS · T32NS007205 · United States
NINDS NIH HHS · T32 NS007205 · United States
NIA NIH HHS · P50 AG005681-26 · United States
NIA NIH HHS · P01 AG003991-26 · United States
NINDS NIH HHS · T32 NS007205-28 · United States
NIA NIH HHS · P01 AG003991 · United States
NIA NIH HHS · P50 AG005681 · United States
External Links
PubMed source DOI: 10.1038/nature08538 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2